FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION

ARGIRELINE · SUBTOPIC · SAFETY PROFILE

ARGIRELINE Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of ARGIRELINE.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of ARGIRELINE. Severity, frequency, and attribution depend on the source publication.

  • Topical · rare mild irritation
  • No systemic absorption documented

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for ARGIRELINE.

  • No documented topical-systemic drug interactions

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for ARGIRELINE in the published record:

  • Hypersensitivity to peptide ingredients

FDA REGULATORY STATUS

Cosmetic ingredient · not a drug. No FDA pharmaceutical approval required for topical cosmetic use.

WADA REGULATORY STATUS

Not listed on the WADA Prohibited List (cosmetic ingredient, no systemic exposure).

SAFETY Q+A FROM LITERATURE

Is Argireline FDA-approved?

Argireline is a cosmetic ingredient, not a drug. The FDA does not pre-approve cosmetic ingredients in the same way as drugs. Topical cosmetic use of Argireline is widespread under existing FDA cosmetic-ingredient regulations.

Is Argireline safe for systemic absorption?

Topical Argireline does not produce documented systemic absorption at cosmetic concentrations. The peptide is too large for significant transdermal absorption into the bloodstream. Systemic side effects are not described.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

  • Blanes-Mira C, Clemente J, Jodas G, et al.. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci 2002. PMID 18494888. link
  • Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther 2007. PMID 18045357. link

RELATED PAGES

ARGIRELINE OVERVIEWMECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-25

© 2026 Peppu Studio LLC · For Laboratory Research Use Only